Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)

CompletedOBSERVATIONAL
Enrollment

1,804

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
GliomaAstrocytoma
Interventions
DRUG

Temozolomide (for newly diagnosed malignant glioma)

"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."

DRUG

Temozolomide (for relapsed malignant glioma)

"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."

RADIATION

Radiotherapy (for patients with newly diagnosed malignant glioma)

Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00705198 - Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) | Biotech Hunter | Biotech Hunter